What are the classifications of maternal diabetes?
Why are the classifications important?
What are the risks to the infant?
What can be done to decrease the risk of complications to the infant?
What special tests may be required for a diabetic mother during pregnancy?
What special tests may be required for the infant after birth?
What special treatments may be required for the infant after birth?
What is the risk of the infant developing insulin-dependant diabetes?
Jan E. Paisley, M.D.
Fellow in Neonatal-Perinatal Medicine
William W. Hay, Jr., M.D.
Professor of Pediatrics, Director of the Training Program in Neonatal-Perinatal Medicine Director of the Neonatal Clinical Research Center
Section of Neonatology, Department of Pediatrics
University of Colorado School of Medicine
The classifications of maternal diabetes are outlined in Table 1.
* Modified from Diabetes Complicating Pregnancy: The Joslin Clinic Method. New York: Wiley-. Liss 1995. 2nd Ed. Florence M. Brown, John W. Hare.
The classification of diabetes during pregnancy is important because the outcome of both the mother and the baby are related to the severity and the duration (represented by the different classes) of the mother's diabetic condition.
In mothers with gestational diabetes, there is an increased risk of large (macrosomic) babies and babies with low blood sugars (hypoglycemia) after birth; however, the overall risk of complications is low.
Large babies and babies with low blood sugars also are associated with Classes A, B, C, and D.1 Large (macrosomic) babies increase the need for cesarean section delivery because the baby can be too big to pass through the mother's pelvis and vaginal canal.
Class F mothers have the highest risk of delivering abnormally small babies with poor growth while inside the mother's uterus.1 Class F mothers also have an increased risk of anemia, high blood pressure (hypertension), and decreased kidney function.
Class H mothers have an increased risk of a heart attack or heart failure and sudden death, along with an increased risk of producing abnormally small babies.
Class R mothers have an increased risk of worsened retinopathy, bleeding into the eye (vitreous hemorrhage), or detachment of the retina. They also have an increased risk of delivering small babies, most often by cesarean section.
All classes have an increased risk of abnormally large amounts of amniotic fluid (polyhydramnios). Polyhydramnios increases the risk of pre-term labor and delivery, delivery of the baby's umbilical cord before the baby (cord prolapse), or early separation of the placenta from the uterus (placental abruption). Cord prolapse and placental abruption can dangerously cut off blood supply to the placenta and the baby.
Infants of diabetic mothers, or IDMs, have a significantly increased risk of breathing problems (respiratory distress), especially if they are born before 37 weeks, because their lungs are slower to mature.
Approximately 30% to 40% of IDMs have low blood sugar (i.e., glucose is less than 40 mg/dl) after birth. This condition usually occurs early after birth, often by one to two hours of age. Low blood sugar occurs because of excess insulin in the baby. The excess insulin was produced in the baby while inside the mother's uterus in response to high blood sugars delivered across the placenta from the mother's blood. Prolonged or severe low blood sugar (i.e., hypoglycemia) can cause seizures and brain damage. Therefore, IDMs will have their blood sugars checked (usually by "heel stick") shortly after birth and then several times over the next one to two days.
Approximately 20% of IDMs will have low calcium. If a baby is very sick, shaky, or lethargic, or has seizures despite normal blood glucose, a blood calcium measurement should be performed.
An abnormally high red blood cell count (polycythemia) can occur in IDMs, increasing their risk of jaundice (yellow skin color), feeding difficulties, respiratory distress, or lethargy. The risk of jaundice is increased significantly in IDMs even if they are not polycythemic. One study found that 19% of IDMs developed bilirubin levels greater than 16 mg/dl. Bilirubin is the yellow pigment that comes from the red blood cells and produces the yellow skin color. When there is too much bilirubin in a baby's blood, it can cause brain damage. Fortunately, this problem is treated easily with light treatment (phototherapy).
The incidence of major congenital anomalies (birth defects) is increased from 6% to 9% in IDMs, compared to a rate of 2% in the general population. The frequency of congenital anomalies is not increased in gestational diabetes; however, two-thirds of these anomalies involve the brain, the nervous system, or the heart. Caudal agenesis (failure of formation of the lower vertebrae and sacrum of the spine) more frequently occurs in IDMs whose mothers had poor blood sugar control around the time of conception and during the first few weeks of pregnancy.
A significant decrease in the incidence of congenital anomalies has been reported with rigorous glucose control in the periconception period.2 Congenital anomalies can be reduced even more if the mother takes folate supplements during the early part of pregnancy.
Poor feeding is a common problem that affects up to 37% of IDMs, often prolonging the hospital stay.
Macrosomia (large birth weight, i.e., larger than 4 kilograms, or 8 pounds) occurs in about one-third of IDMs, and it correlates with high blood sugars and serum fat concentrations in the third trimester of pregnancy.3 Usually, macrosomia is not seen in those mothers with more severe and longer-standing diabetes (e.g., Classes F and R).
Poor heart function or myocardial dysfunction is rare, but increased, in IDMs because of the enlargement of the septum or the wall between the ventricles (the two large pumping chambers of the heart). This condition is called ventricular septal hypertrophy, and can cause congestive heart failure, poor cardiac output, and heart enlargement. However, it often has no associated problems. Sometimes, a heart murmur is heard when IDMs have poor heart function.
Even when there are associated problems with the heart, they usually resolve by two weeks, and the hypertrophy resolves by four months. Good diabetic control during pregnancy can reduce the incidence and the severity of this complication.
Renal vein thrombosis or clotting of the vessel draining blood from the kidney, causing the kidney to swell, is rare; however, it can occur before or after birth in IDMs. It is caused by abnormally low blood anticoagulants that may develop in the baby whose mother is poorly controlled for her diabetes during pregnancy.
Small left colon syndrome can occur in IDMs. This syndrome can cause the delayed passage of a stool after birth, resulting in abdominal distention and a delay in normal feeding.
Good glucose control and prevention of ketoacidosis prior to conception and in the first two months of pregnancy will decrease the risk of congenital anomalies. Later in the pregnancy, glucose control is important to prevent macrosomia, hypoglycemia (after birth), and ventricular septal hypertrophy of the baby's heart. It generally is recommended that the mother's fasting blood glucose should be from 70 to 90 mg/dl, and, two hours after eating, her blood glucose should be less than 120 mg/dl.2
If a pregnant diabetic woman participates in a program of pregnancy management and surveillance from before conception until delivery, she has at least a 95% chance of having a completely healthy child.1
Early screening for congenital anomalies usually includes a serum alpha-fetoprotein level of the mother to screen for open neural tube defects (spina bifida) and a detailed ultrasound at 18 to 20 weeks. Follow-up ultrasounds may be required for polyhydramnios (increased amniotic fluid), abnormal fetal growth, or early separation of the placenta.
Tests of fetal well being, including daily fetal movement counts and biweekly biophysical testing (ultrasound and fetal heart rate monitoring), usually begin at 28 to 32 weeks.
An amniocentesis may be performed prior to delivery if the mother is at less than 38 weeks gestation to document fetal lung maturity.
The mother's glucose will be monitored closely during labor, and insulin and glucose treatments often will be adjusted.
The baby will require frequent blood glucose checks after birth, beginning in the first two hours of birth. These check-ups usually are continued every 2 to 4 hours for at least 24 hours.
The red blood cell count, or hematocrit, will be checked after birth to ensure that the baby does not have polycythemia. If significant jaundice occurs, bilirubin levels will be checked.
If the baby has jitteriness, lethargy, or poor feeding, despite normal glucoses, the calcium level will be checked.
A thorough physical examination will be performed to look for any physical abnormalities and to listen to the heart for any evidence of a heart murmur.
The baby's long-term development will be followed; studies have shown a mild decrease in IQs (93 versus 102) of IDMs with a maternal history of ketones in the urine (ketonuria) during pregnancy, as compared to IDMs with no maternal ketonuria.2 However, significant differences in mental development have not been found between IDMs with good sugar control without ketonuria and other normal babies.
If the baby is well after birth, he/she should be nursed or given formula in the first hour. The first blood sugar should be checked within two hours of birth or sooner if the baby develops jitteriness, lethargy, or seizures. If the blood sugar is low (less than 40 mg/dl), the baby should be fed immediately, and the blood sugar rechecked within one to two hours. If the blood sugar is extremely low (less than 25 mg/dl), if the baby is sick or unable to eat, or if the blood sugar remains low despite feeding, an IV with glucose water should be started for the baby. The blood sugar will be rechecked frequently until it is normal and stable.
If congenital anomalies exist, they will need to be treated accordingly; some birth defects may require surgery.
If the baby develops significant jaundice, phototherapy may be required for a short period (usually from two to five days) to break down the bilirubin in the skin.
If the lungs are not mature, the baby could require help with breathing using a machine called a respirator. The baby also could benefit from surfactant. Surfactant is a soap suds-like material that is administered to help lubricate and expand the lungs. Surfactant often is deficient in immature lungs, and most commonly occurs in those IDMs born at less than 37 weeks.
If the baby has difficulty feeding, he/she may require intermittent gavage feeds with a feeding tube. Extra time in the hospital may be required for the baby to learn to feed by either the breast or the bottle.
If the baby develops abdominal distention or has difficulty stooling, a gastrointestinal x-ray with gastrograffin may be required to check if a microcolon is present.
In a series of studies from the Joslin Diabetes Center, only 2% to 3% of IDMs developed insulin-dependant diabetes mellitus before 20 years of age. The risk of subsequent diabetes is slightly higher if both the mother and the father have insulin-dependent diabetes. The risks and the complications to the baby outlined herein do not pertain when only the father has insulin-dependant diabetes.
Cloherty JP, Stark AR. Manual of neonatal care. Philadelphia, Lippencott-Raven, 1997.
Fanaroff AA, Martin RJ. Metabolic and endocrine disorders. In: Neonatal-perinatal medicine: diseases of the fetus and infant. 6th ed. St. Louis: Mosby-Year Book, Inc.
About the Author
Dr. Paisley is a second year fellow in Neonatal-Perinatal Medicine in the Section of Neonatology, Department of Pediatrics, University of Colorado School of Medicine in Denver, Colorado. Jan trained in Pediatrics at the University of Utah and was honored to receive a highly prestigious Pediatric Scientist Development Program award.
Jan preferred clinical practice, however, and she has been working for the past 7 years as a general Pediatrician in Ft. Collins, Colorado.
She joined the Neonatal-Perinatal Medicine Training Program in 1998 and is working with Dr. Adam Rosenberg and Dr. William Hay on aspects of cerebral glucose metabolism in a fetal animal model and in newborn human infants.
Dr. Hay is a Professor of Pediatrics at the University of Colorado School of Medicine, Denver, Colorado.
He is the Director of the Training Program in Neonatal-Perinatal Medicine, Director of the Neonatal Clinical Research Center (as Associate Director of the National Institutes of Health and Department of Pediatrics sponsored Pediatric Clinical Research Center), and Scientific Director of The Perinatal Research Center at the University of Colorado Health Sciences Center.
Dr. Hay holds three NIH research grants and a NIH Training Grant in Perinatal Medicine and Biology.
His clinical and basic research interests focus on fetal physiology, fetal and neonatal nutrition and metabolism, glucose disorders in preterm infants, small-for-gestational aged infants, and infants of diabetic mothers, and oxygen monitoring.
Dr. Hay is Secretary-Treasurer of the American Pediatric Society and is a member of the NIH Human Embryology and Development Study Section. He travels widely around the United States and internationally as a visiting scientist and professor.
Dr. Hay also is the senior editor for Current Pediatric Diagnosis and Treatment (a Lange Publication) and co-editor of NeoReviews (American Academy of Pediatrics).
Copyright 2012 Jan E. Paisley, M.D., and William W. Hay, Jr., M.D., All Rights Reserved
The information contained in these topics is not intended nor implied to be a substitute for professional medical advice, it is provided for educational purposes only. You assume full responsibility for how you choose to use this information.
Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Talk with your healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.
By using this website, you accept the information provided herein "AS IS." Neither RemedyConnect nor the providers of the information contained herein will have any liability to you arising out of your use of the information contained herein or make any express or implied warranty regarding the accuracy, content, completeness, reliability, or efficacy of the information contained within this website.
RemedyConnect, Inc. has created this privacy statement in order to demonstrate our firm commitment to your privacy. The following discloses our information gathering and dissemination practices for this website: http://www.remedyconnect.com.
We do not acquire any more information about website visitors than is required by law or is otherwise necessary to provide a high level of service efficiently and securely. Our site's registration form requires users to give us contact information (e.g., their name and e-mail address) and demographic information (e.g., children's birth months, but not birth dates). We use customer contact information from the registration form to (1) send the user pertinent medical and parenting information and (2) allow your local health provider lists of who is registering on that provider's site as a parent/guardian, staff member, doctor, or visitor. Users may opt-out of receiving future mailings; see the choice/opt-out section below.
We use your IP address to help diagnose problems with our server and to administer our Website. Your IP address is used to help identify you and to gather broad demographic information.
Demographic and profile data is also collected at our site. We may use this data to tailor the visitor's experience at our site, showing them content that we think they might be interested in, and displaying the content according to their preferences.
Our site may use order forms to allow users to request information, products, and services.
We will respect your doctor's right to privacy. A doctor typically does not give his/her e-mail address to the parents/guardians of patients. We will not provide the e-mail addresses of doctor(s) in the local practice to users of their site without the doctor(s)' permission. Their site is restricted to use by whomever they wish, and they may deny access to their site to one or more prior users. In unusual cases, doctors may change their private site's access code and arrange for us to e-mail the new access code to approved users.
This site contains links to other sites. RemedyConnect.com is not responsible for the privacy practices or the content of such Websites. See Disclaimers.
We will provide individually-identifiable information about website users to third parties only if we are compelled to do so by order of a duly-empowered governmental authority, we have the express permission of the visitor, or it is necessary to process transactions and provide you services from our affiliates: Live Agent Answering Service, Digital Answering Service, Medical Answering Service and Pediatric Answering Service.
This site may make chat rooms, forums, message boards, and/or news groups available to its users. Please remember that any information that is disclosed in these areas becomes public information and you should exercise caution when deciding to disclose your personal information.
This site has security measures in place to protect the loss, misuse and alteration of the information under our control. For further information regarding our security, please contact us at firstname.lastname@example.org. If you have any concerns regarding the security of information, please do not provide any information to RemedyConnect, Inc. until you are comfortable with our security measures.
You may correct or update your User Registration information at any time, by visiting the User Registration section and providing your personal password that you set at registration. If need be, please email us at email@example.com.
Our site provides users the opportunity to opt-out of receiving e-mail communications from our partners or us, except communications approved by your doctor's practice office. To so opt-out, please email us at firstname.lastname@example.org. To be removed as a user, please email us at the same address. If need be, you may mail requests to us at RemedyConnect, Inc., 9200 E. Mineral Avenue, Suite 100, Centennial, CO 80112. Our telephone number is 303-793-0703.
If you have any questions about this privacy statement, the practices of this site, or your dealings with this Website, you can contact us by email at email@example.com or by mail at our address above.